MedTrace Logo

Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US

NCT00795093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 552

Last updated 2010-05-11

No results posted yet for this study

Summary

The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Sponsors & Collaborators

  • i3 Innovus

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Meg Good · i3 Innovus

  • Marie Sundin · AstraZeneca

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00795093 on ClinicalTrials.gov